Background: Currently, the accepted "gold standard" method for bone mineral density (BMD) measurement and osteoporosis diagnosis related to the reference axial anatomical sites is dual-energy X-ray absorptiometry (DXA). However, actual DXA effectiveness is limited by several factors, including intrinsic accuracy uncertainties and specific errors in patient positioning, image segmentation, and post-acquisition data analysis, as documented by very recent literature [1]. This may affect the comparative evaluation of the effectiveness of novel diagnostic methods whose validation studies adopt DXA outcomes as standard reference to assess diagnostic performance. Objectives: To assess the impact of DXA errors on the performance of an innovative ultrasound parameter for osteoporosis diagnosis on the femoral site, known as Osteoporosis Score (OS). Methods: 202 patients aged in 46-75 years underwent two diagnostic investigations on the femoral neck: a conventional femoral DXA and an echographic scan performed by employing the innovative EchoSound technology [2]. Initially, the performance of the OS parameter was evaluated considering all the available DXA reports as reference in the data analysis, and calculating the corresponding accuracy in patient classification (osteoporotic, osteopenic, or healthy) and the correlation coefficient between the DXA-measured BMDs and the OS-derived BMD values. At a later stage, the DXA errors were taken into account by performing a strict quality control on DXA reports: all those cases affected by a typical inaccuracy [1] were excluded from the analysis and the actual diagnostic accuracy of the EchoSound technology was re-assessed by analysing only the reliable DXA reports. Intra-and inter-operator repeatability of OS-derived BMD values were also measured in a group of patients. Results: A diagnostic accuracy of 84.4% (r =0.78, p<0.001) was obtained for the EchoSound approach when all the DXA reports were included in the analysis. In the second part of the study, 61 out of the initial 202 (30.4%) patients were excluded from the analysis because their DXA reports were affected by specific errors. An actual diagnostic accuracy of 94.2% was then obtained on the remaining 141 patients, together with a high correlation between DXA-measured BMDs and OS-derived BMD values (r =0.88, p<0.001). Intra-and inter-operator repeatability of OS-derived BMD values, expressed in terms of the root mean square coefficient of variation (RMS-CV), resulted equal to 0.29% and 0.34% for intra-and inter-operator variability, respectively, therefore documenting a very good measurement repeatability. Conclusions: Undetected DXA errors had an impact on the accuracy evaluation of EchoSound femoral neck densitometry, causing an underestimation of OS performance in osteoporosis diagnosis. The quality control analysis on DXA reports can be useful to study the actual performance of different ultrasonic methods that considered routine DXA reports as the gold standard reference. 
4 Rheumatology, Taher Sfar Mahdia, mahdia, Tunisia Background: Osteoporosis is defined as a skeletal disorder characterized by lowbone mass predisposing to an increased risk of fracture. At present, the evaluation of bone mineral density (BMD) is the main diagnostic tool in osteoporosis, and it is the most effective and accurate measurement for identifying and monitoring the disease. However, several studies have been conducted with the object of detecting whether these skeletal changes in the mandible are specific to the osteoporotic stage. Objectives: The purpose of this study was to determine whether the madibular indices on panoramic radiographs are useful for identifying women with osteoporosis or osteopenia (low BMD). Methods: Tunisian women aged from 30 to 60 years,who consulted the Rheumatology department of Fattouma Bourguiba university hospital in2017.The measure the BMD using the dual-energy X-ray absorptiometry (DEXA), were recruited to participate in this case-control study.Among the 60 women selected, 30 were diagnosed with osteoporosis or osteopenia (T-score <-1; cases) and 30 with normal T-score (T-score >-1; controls). The mandibular cortical index (MCI), the mental index (MI), the panoramic mandibular index (PMI) and the alveolar crest resorption degree (M/M ratio)were measured from digital panoramic radiographs in the right and left mandibles and the mean was calculated for each subject. This study showed that the MI and the PMI were significantly smaller in the group with osteoporosis/osteopenia. However, the M/M ratio was not significantly different.Therefore, the MCI was significantly more affected in the osteoporosis/osteopenia group. Conclusions: In our study, we proved that the MI, PMI and MCI values were affected in women with osteoporosis/osteopenia, compared with normal patients. Therefore, these indices could be used as an ancillary method in the diagnosis of osteoporosis in women.
References:
[1] C S Valerio et al, Dentomaxillofacial Radiology (2013) Background: Both periodontitis and osteoporosis have similar sign of bone resorption in nature and have multifactorial etiologic factors, although the mediator factors or mechanism may be different. How to prevent and treat these two bone-loss diseases is always an important issue in public health. However, the relationship of them is still uncertain. Objectives: The aim of our study is to evaluate the relationship between periodentitis and osteoporosis. Methods: Tunisian women aged from 30 to 60 years, who consulted the Rheumatology department of Fattouma Bourguiba university hospital between Febrary to December 2017. The measure the bone mineral density (BMD) using the dual-energy X-ray absorptiometry (DEXA), were recruited to participate in this case-control study. Among the 60 women selected, 30 were diagnosed with osteoporosis or osteopenia (T-score< -1; cases) and 30 with normal T-score (T-score> -1; controls). The oral examination was done by a dentist in the stomatology department in the same hospital.
Results:
The mean age of patients with osteoporosis/osteopenia was 58.61±8.11 [51-81 and 56.07±9.72 [40-76] Background: Osteoprosis is a health problem that if is left untreated,can lead to serious health & economical complications.It is also very common in postmenopausal women. Mineral deficiency, smoking, low BMI, some certain diseases and some medications can also cause osteoprosis. H.Pylori infection can also increase levels of inflammatory cytokines and bone turn over regulatory cytokines,as a result, it is likely that H. pylori infected patients are at increased risk for osteoprosis. Objectives: the present study was done to understanding the association between H.Pylori seropositivity and osteoprosis in postmenopausal women. Methods: The study population consisted of 34 osteoporotic patients and 73 healthy controls. Serum levels of h.pylori antibody (IgA,IgG) were measured by ELISA method. Results: There was no difference in levels of IgA and IgG h.pylori antibody between patients and healthy controls IgA seropositivity was 70.6% in osteoporotic women and 54.8% in healty women (p value: 0.1). Also H. pylori IgG seropositivity was 82% in osteoporotic women and 75.3% in healthy women (p value: 0.4). We didnot find any correlation between H. pylori seropositivity and bone mineral density in post menopausal women. Conclusions: In this study, we found that Helicobacter pylori infection does not increase the osteoporotic chance and is not a reliable risk factor for osteoporosis. greater sampele size, gastric biopsy to detect atrophic gastritis, bone turn over factors and Cag detection is recommended in order to achieve more accurate results References: Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density," Arquivos de Gastroenterologia, vol. 44, no. 3, pp. 2007,266-270. [3] Figura N Background: Zoledronate is recommended by European guidelines for the treatment of osteoporosis particularly where first-line oral drugs are ineffective or contraindicated. EULAR's guidelines are complimented by UK organisations including the National Institute of Health and Care Excellence (NICE), National Osteoporosis Guidelines Group (NOGG), British Society of Rheumatology (BSR) and the National Osteoporosis Society (NOS). Objectives: The aim of our audit was to ascertain whether our use of zoledronate was compliant with current guidelines and review the real life experience. Methods: We performed a retrospective audit of fifty patients who were commenced on zoledronate for the treatment of osteoporosis during 2012-2016 in our Trust. Data gathered included the reasons for commencement, whether patients had appropriate monitoring and the effect it had on DEXA and FRAX scores. Results: The age ranged from 44-88 years; 67% were between 60-80 years with 80% females. Vertebral fragility fractures were the most common type of fracture (42%). Zoledronate was commenced primarily because of either intolerance or inefficacy to oral anti-osteoporotic treatment (Table 1) . It was commenced as first line in 20% because of contraindications to oral drugs. Almost 70% of our patients received zoledronate for two or three years. There was an improvement by 43% and 38% in the DEXA t-score for the spine and hip respectively. Stable t-scores were recorded for the spine and hip in 49% and 54% respectively, whereas 8% deteriorated. Three patients sustained a fragility fracture and a further 11 experienced side effects (Table 2) ; five patients consequently stopped treatment. Only 3% had recorded FRAX scores pre-or post-zoledronate treatment. All of our patients had their calcium and renal function measured before each zoledronate infusion whilst over 80% had their vitamin D checked. All of our patients had dental checks prior to treatment. Following post-treatment DEXA scans 46% continued zoledronate and 16% were on a drug-free holiday. A third were switched to denosumab due to ineffectiveness, side effects or contraindications. Background: Patients with autoimmune diseases are at increased risk of early onset osteoporosis due to multiple reasons including prolonged exposure to corticosteroids and the disease process itself in RA patients. Same patients are more likely to be on TNF inhibitors or other biologics, which causes them to be at an increased risk of infections. Denosumab, an anti-RANK ligand inhibitor, itself a biologic, used to treat osteoporosis, is associated with increased infection risk as Receptor activator of nuclear factor kappa B ligand (RANKL) is also expressed on activated T and B lymphocytes (1). It is unknown if there is an added risk of infections when TNF inhibitors/biologic agents and denosumab are used concomitantly. Objectives: To determine if denosumab and biologics are associated with increased infection risk. Methods: Data was collected and analyzed on 40 patients in the rheumatology clinic who had been on denosumab and TNF inhibitor/ other biologic for 66 months at the Keck Medical Center of USC.
